12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Effient prasugrel: Phase III data

The double-blind, international Phase III TRILOGY ACS trial in 9,326 patients showed that Effient plus low-dose aspirin missed the composite primary endpoint of reducing the incidence of cardiovascular death, MI or stroke at 30 months in patients under 75 years of age (n=7,243) vs. Plavix clopidogrel plus low-dose aspirin (13.9% vs. 16%, p=0.21). The trial enrolled patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) who were medically managed without revascularization. In the overall population, 18.7% of patients receiving Effient achieved...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >